Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EWTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$14.12-3.5%$14.16$10.60▼$38.12$1.49B0.251.29 million shs759,673 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics+1.67%+6.55%-0.81%-1.42%-30.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEWTXEdgewise Therapeutics1.6689 of 5 stars3.40.00.00.02.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWTXEdgewise Therapeutics 2.80Moderate Buy$40.00183.29% UpsideCurrent Analyst Ratings BreakdownLatest EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025EWTXEdgewise TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$42.006/5/2025EWTXEdgewise TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$48.004/30/2025EWTXEdgewise TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$41.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWTXEdgewise Therapeutics-$133.81M-$1.55N/AN/AN/AN/A-30.95%-29.45%8/6/2025 (Estimated)Latest EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025EWTXEdgewise Therapeutics-$0.42N/AN/AN/AN/AN/A5/8/2025Q1 2025EWTXEdgewise Therapeutics-$0.45-$0.43+$0.02-$0.43N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEWTXEdgewise TherapeuticsN/A20.9920.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWTXEdgewise TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipEWTXEdgewise Therapeutics23.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWTXEdgewise Therapeutics60105.20 million80.79 millionOptionableEWTX HeadlinesRecent News About These CompaniesReadystate Asset Management LP Boosts Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)July 22 at 1:15 PM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTXJuly 22 at 10:00 AM | prnewswire.comJennison Associates LLC Purchases New Stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)July 22 at 6:50 AM | marketbeat.comEdgewise Therapeutics Inc (EWTX) - Investing.comJuly 20, 2025 | investing.comEWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. ...July 19, 2025 | gurufocus.comEWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law FirmJuly 19, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTXJuly 18, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTXJuly 17, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Edgewise Therapeutics, Inc. - EWTXJuly 14, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTXJuly 12, 2025 | prnewswire.comEdgewise Therapeutics (NASDAQ:EWTX) Trading Up 7.9% - Still a Buy?July 9, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTXJuly 7, 2025 | prnewswire.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of "Moderate Buy" by AnalystsJuly 5, 2025 | marketbeat.comEdgewise Therapeutics Reports Positive Results for Muscular Dystrophy TreatmentJuly 4, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX - MorningstarJuly 3, 2025 | morningstar.comMEdgewise Therapeutics, Inc. (EWTX) Cash Flow - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTXJuly 3, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Edgewise Therapeutics (EWTX) and Arcturus Therapeutics (ARCT)July 2, 2025 | theglobeandmail.com13 Best Up and Coming Stocks to Invest In NowJuly 2, 2025 | insidermonkey.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTXJuly 2, 2025 | prnewswire.comWhat is HC Wainwright's Forecast for EWTX Q2 Earnings?July 2, 2025 | marketbeat.comMedia Sentiment Over TimeEWTX Company DescriptionsEdgewise Therapeutics NASDAQ:EWTX$14.12 -0.51 (-3.49%) Closing price 04:00 PM EasternExtended Trading$14.10 -0.02 (-0.14%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
